CRISPR RNPs and the Future of Cell and Gene Therapy

CRISPR RNPs Advancing Gene & Cell Therapy

Ribonucleoproteins (RNPs) have many advantages in the development of ex vivo cellular therapies, a rapidly growing segment for CRISPR therapeutics. However, the regulatory & production challenges can hold up new therapies from reaching the clinic.

EXPLORE THE ALDEVRON ADVANTAGE

Supporting GMP-grade RNP Manufacturing* with Scalability, Accelerated Lead Times, and Flexibility

 *Aldevron provides RNPs only to customers who are duly licensed, including to make and have made RNPs, for their intended use.

Allison Pappas, Ph.D.

Senior Manager, Client Relations - Gene Editing, Aldevron

Allison Pappas leads Aldevron's Gene Editing Client Relations team and specializes in helping clients obtain high quality gene editing enzymes and RNPs, from Research grade through GMP. She has a strong understanding of GMP requirements, having worked in GMP QC release and stability of biopharmaceuticals before joining Aldevron. Her scientific expertise is in the evolution and characterization of RNA:protein complexes. Dr. Pappas holds a Ph.D. in genetics from Iowa State University and a B.S. in microbiology from Indiana University - Bloomington.

Ribonucleoproteins (RNPs) have many advantages in the development of ex vivo cellular therapies, a rapidly growing segment for CRISPR therapeutics. However, the regulatory & production challenges can hold up new therapies from reaching the clinic.

READ THE WHITEPAPER

READ THE ARTICLE

TALK TO AN EXPERT

Allison Pappas, Ph.D.

Book A Time